Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GenVec, Inc.
GenVec Presents Encouraging Data on TNFerade in Esophageal Cancer
June 11th, 2008
GenVec, Inc. (Nasdaq:GNVC) will present an overview of TNFerade(TM) development and an update on long-term survival data from its Phase II clinical trial using TNFerade in patients with esophageal cancer this morning at the American Society of Gene Therapy (ASGT) 11th Annual Meeting in Boston, MA. Dr. Mark Thornton, GenVec's Senior Vice President of Product Development, will present data on GenVec's multi-center, dose escalating study of TNFerade in patients with resectable stage II and III esophageal cancer. Following treatment with TNFerade and chemoradiation, the median overall survival of patients in this study was 48.4 months. This compares favorably to a...
Source: Vaccine Weekly (2008-06-11)
|
